<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clinics (Sao Paulo)</journal-id><journal-id journal-id-type="iso-abbrev">Clinics (Sao Paulo)</journal-id><journal-id journal-id-type="publisher-id">clin</journal-id><journal-title-group><journal-title>Clinics</journal-title></journal-title-group><issn pub-type="ppub">1807-5932</issn><issn pub-type="epub">1980-5322</issn><publisher><publisher-name>Faculdade de Medicina / USP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7213670</article-id><article-id pub-id-type="publisher-id">cln_75p1</article-id><article-id pub-id-type="doi">10.6061/clinics/2020/e1912</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding, and Antibody-dependent Enhancement (ADE)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Peron</surname><given-names>Jean Pierre Schatzmann</given-names></name><xref ref-type="aff" rid="aff1">I</xref><xref ref-type="aff" rid="aff2">II</xref><xref ref-type="aff" rid="aff3">III</xref><xref ref-type="corresp" rid="c1-cln_75p1">*</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1638-8866</contrib-id></contrib><contrib contrib-type="author"><name><surname>Nakaya</surname><given-names>Helder</given-names></name><xref ref-type="aff" rid="aff2">II</xref></contrib><aff id="aff1"><label>I</label>Laboratorio de Interacoes Neuroimunes, Departamento de Imunologia - ICB IV, Universidade de Sao Paulo (USP), Sao Paulo, SP, BR</aff><aff id="aff2"><label>II</label>Plataforma Cientifica Pasteur-USP, Universidade de Sao Paulo (USP), Sao Paulo, SP, BR</aff><aff id="aff3"><label>III</label>Programa de Pos Graduacao em Alergia e Imunopatologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR</aff></contrib-group><author-notes><corresp id="c1-cln_75p1"><sup>*</sup>Corresponding author. E-mail: <email>jeanpierre@usp.br</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>75</volume><elocation-id>e1912</elocation-id><history><date date-type="received"><day>8</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 CLINICS</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The world is currently facing a serious SARS-CoV-2 infection pandemic. This virus is a new isolate of coronavirus, and the current infection crisis has surpassed the SARS and MERS epidemics that occurred in 2002 and 2013, respectively. SARS-CoV-2 has currently infected more than 142,000 people, causing 5,000 deaths and spreading across more than 130 countries worldwide. The spreading capacity of the virus clearly demonstrates the potential threat of respiratory viruses to human health, thereby reiterating to the governments around the world that preventive health policies and scientific research are pivotal to overcoming the crisis. Coronavirus disease (COVID-19) causes flu-like symptoms in most cases. However, approximately 15% of the patients need hospitalization, and 5% require assisted ventilation, depending on the cohorts studied. What is intriguing, however, is the higher susceptibility of the elderly, especially individuals who are older than 60 years of age, and have comorbidities, including hypertension, diabetes, and heart disease. In fact, the death rate in this group may be up to 10-12%. Interestingly, children are somehow less susceptible and are not considered as a risk group.</p><p>Therefore, in this review, we discuss some possible molecular and cellular mechanisms by virtue of which the elderly subjects may be more susceptible to severe COVID-19. Toward this, we raise two main points, i) increased ACE-2 expression in pulmonary and heart tissues in users of chronic angiotensin 1 receptor (AT1R) blockers; and ii) antibody-dependent enhancement (ADE) after previous exposure to other circulating coronaviruses. We believe that these points are pivotal for a better understanding of the pathogenesis of severe COVID-19, and must be carefully addressed by physicians and scientists in the field.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>Immunopathology</kwd><kwd>ACE-2</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The world is facing a major public health crisis due to the pandemic caused by a recently-described coronavirus, named SARS-CoV-2 <xref rid="B01" ref-type="bibr"/><xref rid="B02" ref-type="bibr"/><xref rid="B03" ref-type="bibr">1-3</xref>. Reaching proportions that far surpass those of SARS and MERS, the SARS-CoV-2 epidemic started in Wuhan, China in December 2019, but has now spread to more than 130 countries worldwide and has infected approximately 142,000 people, with more than 5,000 deaths being attributed to it (WHO, March 13<sup>th</sup> 2020) <xref rid="B04" ref-type="bibr">4</xref>. Sequencing analysis of the viral genome has revealed mutations in the spike protein&#x02014;which is essential for SARS-CoV-2 attachment and invasion into host cells&#x02014;may have favored the spill over from bats to humans <xref rid="B01" ref-type="bibr">1</xref>. Most patients infected with coronaviruses develop a mild flu-like disease, in which the most common symptoms are fever and cough. However, in a study of 1,099 patients from 552 hospitals from 30 provinces of China in 2020, Guan W et al. <xref rid="B05" ref-type="bibr">5</xref>, revealed that 15.7% of the patients who develop severe disease have increased difficulty in breathing because of pneumonia. Radiological imaging of the lungs revealed opacity in 56.4% of the patients. Approximately 2.7% of the patients needed assisted ventilation, and 1.4% died <xref rid="B01" ref-type="bibr">1</xref>.</p><p>However, coronavirus disease (COVID-19) may rapidly develop into severe acute respiratory syndrome (SARS) in elderly subjects (&#x0003e;60 yr), especially in those with comorbidities, such as hypertension, diabetes, and pulmonary diseases <xref rid="B01" ref-type="bibr">1</xref>,<xref rid="B04" ref-type="bibr">4</xref>,<xref rid="B06" ref-type="bibr">6</xref>. What is intriguing is that, unlike in the case of influenza <xref rid="B07" ref-type="bibr">7</xref>, children are not included in the risk group, as very few cases of severe COVID-19 in children have been reported, and there have been no reports of death in children under the age of 9. This raises questions regarding the cellular and molecular mechanisms associated with the severity of COVID-19. Understanding and elucidating such mechanisms may greatly improve our knowledge of the pathogenesis of the disease, and thus guide health professionals as to how to better treat the elderly population.</p><p>Toward this, we raise two main points of discussion, i) the increased angiotensin-converting enzyme-2 (ACE-2) expression in pulmonary and heart tissues of hypertensive patients with chronic use of AT1R blockers and ii) antibody-dependent enhancement (ADE) after previous exposure to other circulating coronaviruses.</p><sec><title>SARS-CoV-2 and ACE-2</title><p>After entering the host&#x02014;usually through aerosolized viral particles or contact with contaminated surfaces&#x02014;the virus needs to undergo its biological cycle. Spike proteins&#x02014;that are coded by the S gene in one of the open reading frames of the viral genome&#x02014;need to interact with viral receptors on the surface of host cells. SARS-CoV-2 spike proteins bind to angiotensin-converting enzyme-2 (ACE-2), which is expressed in the epithelial cells of the lungs <xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B09" ref-type="bibr">9</xref>. This is the main reason why coronaviruses often cause respiratory disease. Notably, ACE-2 may also be highly expressed in intestinal tissues <xref rid="B09" ref-type="bibr">9</xref>, leading to diarrhea, as observed in 60% of the patients during the SARS-CoV epidemic in 2002. Only a few patients with SARS-CoV-2 infection had diarrhea, although viral particles may be detected in the stool <xref rid="B10" ref-type="bibr">10</xref>. After attaching to the ACE-2 through the receptor-binding domain (RBD) of the S1 and S2 domains of the spike protein, the viral envelope fuses with the host cell membrane and is further internalized. Genetic material, a positive RNA strand of approximately 20-32 kb, is released into the cytoplasm for replication <xref rid="B01" ref-type="bibr">1</xref>. Thus, the importance of ACE-2 expression dynamics for viral infectivity, tropism, and pathogenicity is evident.</p><p>ACE-2, or ACE-related carboxypeptidase, is an 805 amino acid transmembrane protein which is an important member of the renin-angiotensin system that plays a pivotal role in the regulation of blood pressure <xref rid="B11" ref-type="bibr">11</xref>. ACE converts angiotensin I (Ang I) into angiotensin II (Ang II), whereas ACE-2 converts Ang II into angiotensin 1-7 (Ang 1-7) or angiotensin 1-9 (Ang 1-9) <xref rid="B12" ref-type="bibr">12</xref>. Ang II and Ang 1-7 have antagonizing effects, as Ang II binds to angiotensin 1 receptor (AT1R), inducing vasoconstriction and increase in blood pressure, whereas Ang 1-7 binds to AT2R, leading to vasodilatation and decrease in blood pressure <xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>.</p><p>As the renin-angiotensin system affects blood pressure and kidney function, ACE inhibitors and AT1R blockers are widely used in hypertensive and cardiac patients <xref rid="B13" ref-type="bibr">13</xref>. In this context, the chronic use of ACE inhibitors or AT1R antagonists may be of particular relevance for patients infected with SARS-CoV-2, as they may alter the dynamics of ACE-2 expression and thus increase susceptibility to SARS-CoV-2 infection.</p><p>It has already been demonstrated by using hypertensive rat models that AT1R blockade elevates ACE-2 expression. Treatment with losartan and lisinopril, either alone or in combination, significantly increases ACE-2 mRNA in cardiomyocytes of rats. This is associated with higher Ang 1-7 plasma concentrations <xref rid="B14" ref-type="bibr">14</xref>. This was corroborated by analyzing the heart tissue from rats with myocardial infarction that were treated with losartan <xref rid="B15" ref-type="bibr">15</xref>. Concordantly, olmesartan, a more effective AT1R antagonist, significantly increased both cardiac and renal expression of ACE-2 in Wistar&#x02013;Kyoto rats <xref rid="B16" ref-type="bibr">16</xref>. This is in agreement with the use of perindopril, an ACE inhibitor, in rats <xref rid="B17" ref-type="bibr">17</xref>.</p><p>Another interesting feature of the dynamics of ACE-2 expression in tissues is its ability to be cleaved from the cell surface by a metalloproteinase called ADAM17 (TACE) <xref rid="B18" ref-type="bibr">18</xref>. The ACE-2 ectodomain gets cleaved, releasing soluble ACE-2 (sACE-2), whose role has not been fully elucidated. However, it has been shown that a higher concentration of sACE-2 in the plasma correlates with a poorer prognosis after heart failure <xref rid="B19" ref-type="bibr">19</xref>. Notably, sACE-2 may also be detected at higher concentrations in the cerebrospinal fluid in hypertensive patients. This has been corroborated in Nefh<sup>cre</sup>x AT1aR<sup>flox/flox</sup> mice, indicating that ACE-2 and sACE-2 levels in the brain are associated with the etiology of neurogenic hypertension <xref rid="B20" ref-type="bibr">20</xref>.</p><p>Further, it was demonstrated that ACE-2 may be cleaved by other mechanisms. For instance, the SARS spike protein may modulate ADAM17 expression, which in turn cleaves ACE-2 into its soluble form. This was found to be dependent on the cytoplasmic domain of ACE-2, as siRNA against ADAM17 or ACE-2 lacking intracellular domains abrogated this phenomenon <xref rid="B21" ref-type="bibr">21</xref>. Interestingly, increased shedding of ACE-2 correlates with worsening of the disease, probably because of an increase in Ang II instead of Ang 1-7. This leads to increased vascular permeability and local inflammation. Interestingly, ACE-2 cleavage from the cell surface may also occur in lung epithelial cells <xref rid="B22" ref-type="bibr">22</xref>. Thus, cleavage of ACE-2 into sACE-2 would compromise the effect of Ang 1-7 on AT2R, thereby reducing pulmonary hypertension and inflammation.</p><p>Altogether, as depicted in <xref ref-type="fig" rid="f01">Figure 1</xref>, these data show that modulating the renin-angiotensin axis alters ACE-2 expression in several tissues, especially in the lung and heart tissues. The use of ACE inhibitors and AT1R antagonists seems to upregulate ACE-2 expression, facilitating viral attachment and entry. The further presence of the virus itself or some cytokines, including TNF-&#x003b1;, leads to ACE-2 release from the cell membrane, abrogating its function to counteract Ang II.</p><p>Altogether, ACE-2 overexpression may facilitate viral replication in lung tissue and promote lung vascular permeability, a common feature of severe SARS-CoV-2 infection. In summary, this may greatly impact the outcome of SARS-CoV-2 infection in elderly and hypertensive patients, as ACE-2 is the putative attachment and invasion receptor for coronaviruses <xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B23" ref-type="bibr">23</xref>. In fact, the use of TACE inhibitors as SARS antiviral agents has already been proposed in experimental models <xref rid="B02" ref-type="bibr">2</xref>,<xref rid="B03" ref-type="bibr">3</xref>,<xref rid="B24" ref-type="bibr">24</xref>.</p></sec></sec><sec><title>ANTIBODY-DEPENDENT ENHANCEMENT</title><p>ADE is a phenomenon by which viruses use preexisting non-neutralizing antibodies from previous exposure to invade host cells through Fc receptor-mediated internalization. This is most commonly observed during secondary dengue virus (DENV) infection, causing severe hemorrhagic disease <xref rid="B25" ref-type="bibr">25</xref>. Notably, the possibility of ADE between Zika virus (ZIKV), the causative agent of ZIKV congenital syndrome <xref rid="B26" ref-type="bibr">26</xref>, and DENV has been intensely debated recently <xref rid="B27" ref-type="bibr"/><xref rid="B28" ref-type="bibr"/><xref rid="B29" ref-type="bibr">27-29</xref>. Moreover, ADE has been the focus of debate for Ebola <xref rid="B30" ref-type="bibr">30</xref> and HIV <xref rid="B31" ref-type="bibr">31</xref> infections.</p><p>During ADE, preexisting antibodies elicited during a previous viral exposure are not able to neutralize viral particles during a secondary infection with any antigenic-related virus. Instead, IgG-opsonized viral particles then target Fc&#x003b3;R expressed on endothelial and immune cells, facilitating viral internalization into host cells. Further, after intense viral replication, endothelial cells may respond by increasing vascular permeability and allowing exudate extravasation and bleeding. However, monocytes become highly activated and may initiate a cytokine storm <xref rid="B32" ref-type="bibr">32</xref>.</p><p>In the context of SARS-CoV-2, it is plausible to think that ADE occurs. As mentioned in the introduction section, elderly (&#x0003e;60 yr) patients are more susceptible to infection for unknown reasons. As coronaviruses in general are highly prevalent in the global population, causing mild infection and flu-like symptoms, seroconversion into previous circulating coronaviruses is probably widespread. Thus, it is reasonable to infer that elderly patients, for obvious reasons, have been exposed to previous infections more times than younger subjects. This would imply a vaster repertoire of antibodies against coronavirus epitopes produced by long-living plasma cells, which in fact has recently been shown to expand during SARS-CoV-2 infection.</p><p>However, whether these antibodies are either neutralizers or enhancers must be further addressed. It is worth mentioning that, concerning the new SARS-CoV-2, sequencing analysis of the viral genome isolated in Wuhan, China indicated that mutations mainly occurred within the coding sequence of the spike protein, which has less than 40% sequence identity with that of previously circulated coronaviruses <xref rid="B01" ref-type="bibr">1</xref>. These mutations may be responsible not only for the spill over from bats to humans, but also for inducing ADE, as changes in spike epitopes may result in interactions with non-neutralizing antibodies. Corroborating this, a novel epitope, which was lacking in previous isolates, was mapped <xref rid="B33" ref-type="bibr">33</xref>.</p><p>As COVID-19 is not a hemorrhagic disease, it is probable that ADE, if present, is not mediated by endothelial cells. However, it has already been shown that lung epithelial cells express high levels of Fc&#x003b3;RIIa <xref rid="B34" ref-type="bibr">34</xref>. Moreover, immune cells, including monocytes and dendritic cells, highly express this receptor. These populations, especially monocytes, greatly account for the inflammatory infiltrate in the lungs during pneumonia, which is consistent with the transient lymphopenia observed in patients as circulating cells may migrate to the lungs. Conversely, lung imaging of patients with severe COVID-19 shows a great degree of lung opacity, which is consistent with edema and cellular infiltrate <xref rid="B05" ref-type="bibr">5</xref>. Thus, it is feasible that lung-infiltrating monocytes expressing Fc&#x003b3;R greatly favor SARS-CoV-2 replication in the lung tissue, accounting for the greater susceptibility of the elderly patients.</p><p>Corroborating this hypothesis, young individuals and children do not represent the risk group for severe disease, which greatly differs from the case of influenza <xref rid="B07" ref-type="bibr">7</xref>, for instance. In the context of ADE, it is plausible to think that children&#x02014;as they had less or no exposure to previous circulating coronaviruses&#x02014;carry a very restricted repertoire of IgG&#x02014;or only low-affinity IgM&#x02014;which is not capable of inducing ADE. In this context, mapping complementarity determining regions (CDRs) in IgGs from young and elderly individuals would be of great importance not only to find neutralizing antibodies but also to address this hypothesis.</p><p>Additionally, previous studies on MERS and SARS have already highlighted the possibility of ADE. A recent report published by Wan Y et al. elucidated the mechanism by which monoclonal antibodies (mAbs) induce ADE in human cells. Interestingly, mAbs that target the RBD of SARS and MERS spike proteins induced conformational changes in the protein that favors an interaction with dipeptidyl peptidase 4 (DPP4), the receptor for MERS <xref rid="B38" ref-type="bibr">38</xref>. Moreover, immunocomplexes also promoted viral entry. However, increasing concentrations of antibodies block viral invasion, as RBDs become inaccessible.</p><p>This is consistent with previous findings by Wang Q et al.<xref rid="B39" ref-type="bibr">39</xref> who infected the promonocytic cell line HL-CZ&#x02014;that expresses both ACE-2 and Fc&#x003b3;R&#x02014;with SARS-CoV-2 in the presence of increasing concentrations of anti-sera. Their data demonstrated that high concentrations of antibodies neutralized the virus, whereas lower concentrations induced ADE. More interestingly, the anti-sera also recognized spike protein-related antigens.</p><p>Another study on SARS-CoV-2 using Rhesus monkeys showed that immunization with full-length SPIKE glycoprotein led to increased disease severity, mostly to because of an increase in neutralizing antibodies (NAb) <xref rid="B35" ref-type="bibr">35</xref>. The study demonstrated that NAbs switched the phenotype of lung-infiltrating macrophages to a pro-inflammatory M1 profile, instead of the tissue-healing profile M2. This aggravated lung injury and greatly contributed to its pathology. Conversely, previous studies using samples from deceased patients suffering from SARS-CoV infection indicated that NAb titers reached higher levels earlier in these patients, compared to that in patients who survived <xref rid="B36" ref-type="bibr">36</xref>. This may indicate that ADE and the role of preexisting antibodies are in fact very relevant to the overall outcome of the infection.</p><p>Thus, as indicated in <xref ref-type="fig" rid="f02">Figure 2</xref>, circulating antibodies, instead of neutralizing the current circulating SARS-CoV-2, may bind to viral particles and thus promote Fc-mediated internalization by lung epithelial cells and infiltrating monocytes, contributing to the worsening of COVID-19. These are the most recent and mechanistic studies on ADE of coronaviruses thus far. Although the data are consistent, whether the phenomenon of ADE is observed in patients with severe COVID-19 is yet to be determined. Noteworthy, however, is the fact that immune complexes of low-avidity antibodies at sub-optimal concentrations were also responsible for the worsening of the pulmonary disease caused by H1N1 during the 2009 epidemic <xref rid="B37" ref-type="bibr">37</xref>.</p></sec><sec><title>CONCLUSIONS</title><p>SARS-CoV-2 is the newest threat to human health and needs emergency action from governments and public health agencies worldwide, especially because of its pandemic potential as recently declared by the World Health Organization (WHO). In this context, it is essential to rapidly and deeply address all the possibilities concerning the severity of infection, especially in the elderly population that accounts for approximately 10-12% of the mortality rate. Here, we present several relevant aspects that may contribute to the increased susceptibility of the aforementioned population to COVID-19. We believe that i) increased expression of ACE-2 in hypertensive patients being treated with ACE inhibitors and AT1R blockers and ii) previous exposure to circulating coronaviruses with low neutralizing capacity to SARS-CoV-2 may greatly contribute to the increased susceptibility of the elderly patients to COVID-19. To determine whether these hypotheses are correct, further investigations are needed, not only to better understand the etiology of the current SARS-CoV-2 infection, but also to be better prepared for future epidemics.</p></sec><sec><title>AUTHOR CONTRIBUTIONS</title><p>Peron JPS conceived and wrote the manuscript. Nakaya H helped editing the manuscript.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>JPSP is funded by FAPESP (grant numbers: #2017/26170-0 and 2017/22504-1) and CNPq (301287/2016-3). HN is funded by FAPESP (grant numbers: #2017/50137-3, 2012/19278-6, 2018/14933-2, 2018/21934-5, and 2013/08216-2) and CNPq (313662/2017-7).</p></ack><fn-group><fn fn-type="COI-statement"><p>No potential conflict of interest was reported.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B01"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source xml:lang="en">Nature</source>
<year>2020</year>
<volume>579</volume>
<issue>(7798)</issue>
<fpage>270</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>ZG</given-names></name><etal/></person-group>
<article-title>A new coronavirus associated with human respiratory disease in China</article-title>
<source xml:lang="en">Nature</source>
<year>2020</year>
<volume>579</volume>
<issue>(7798)</issue>
<fpage>265</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id>
<pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>
<source xml:lang="en">Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>(10224)</issue>
<fpage>565</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id>
<pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>WHO</collab></person-group>
<source xml:lang="en">World Health Organization - Situation Reports</source>
<year>2020</year>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200315-sitrep-55-covid-19.pdf?sfvrsn=33daa5cb_6">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200315-sitrep-55-covid-19.pdf?sfvrsn=33daa5cb_6</ext-link></comment>
</element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><etal/></person-group>
<article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>
<source xml:lang="en">N Engl J Med</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id>
</element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China</article-title>
<source xml:lang="en">JAMA Intern Med</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id>
</element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>KL</given-names></name><name><surname>Madhi</surname><given-names>SA</given-names></name><name><surname>Widdowson</surname><given-names>MA</given-names></name><name><surname>Byass</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study</article-title>
<source xml:lang="en">Lancet Glob Health</source>
<year>2020</year>
<volume>8</volume>
<issue>(4)</issue>
<fpage>e497</fpage>
<lpage>e510</lpage>
<pub-id pub-id-type="doi">10.1016/S2214-109X(19)30545-5</pub-id>
<pub-id pub-id-type="pmid">32087815</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Berne</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>
<source xml:lang="en">Nature</source>
<year>2003</year>
<volume>426</volume>
<issue>(6965)</issue>
<fpage>450</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1038/nature02145</pub-id>
<pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>ML</given-names></name><name><surname>Lely</surname><given-names>AT</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group>
<article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title>
<source xml:lang="en">J Pathol</source>
<year>2004</year>
<volume>203</volume>
<issue>(2)</issue>
<fpage>631</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1002/path.1570</pub-id>
<pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>BE</given-names></name><name><surname>Ong</surname><given-names>SWX</given-names></name><name><surname>Kalimuddin</surname><given-names>S</given-names></name><name><surname>Low</surname><given-names>JG</given-names></name><name><surname>Tan</surname><given-names>SY</given-names></name><name><surname>Loh</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore</article-title>
<source xml:lang="en">JAMA</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1001/jama.2020.3204</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Sarao</surname><given-names>R</given-names></name><name><surname>Oudit</surname><given-names>GY</given-names></name><name><surname>Yagil</surname><given-names>C</given-names></name><name><surname>Kozieradzki</surname><given-names>I</given-names></name><name><surname>Scanga</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>Angiotensin-converting enzyme 2 is an essential regulator of heart function</article-title>
<source xml:lang="en">Nature</source>
<year>2002</year>
<volume>417</volume>
<issue>(6891)</issue>
<fpage>822</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1038/nature00786</pub-id>
<pub-id pub-id-type="pmid">12075344</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets</article-title>
<source xml:lang="en">Nat Rev Cardiol</source>
<year>2014</year>
<volume>11</volume>
<issue>(7)</issue>
<fpage>413</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1038/nrcardio.2014.59</pub-id>
<pub-id pub-id-type="pmid">24776703</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johansen</surname><given-names>ME</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Griggs</surname><given-names>JM</given-names></name><name><surname>Jackson</surname><given-names>EA</given-names></name><name><surname>Richardson</surname><given-names>CR</given-names></name></person-group>
<article-title>Anti-Hypertensive Medication Combinations in the United States</article-title>
<source xml:lang="en">J Am Board Fam Med</source>
<year>2020</year>
<volume>33</volume>
<issue>(1)</issue>
<fpage>143</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.3122/jabfm.2020.01.190134</pub-id>
<pub-id pub-id-type="pmid">31907256</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>CM</given-names></name><name><surname>Jessup</surname><given-names>J</given-names></name><name><surname>Chappell</surname><given-names>MC</given-names></name><name><surname>Averill</surname><given-names>DB</given-names></name><name><surname>Brosnihan</surname><given-names>KB</given-names></name><name><surname>Tallant</surname><given-names>EA</given-names></name><etal/></person-group>
<article-title>Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2</article-title>
<source xml:lang="en">Circulation</source>
<year>2005</year>
<volume>111</volume>
<issue>(20)</issue>
<fpage>2605</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.510461</pub-id>
<pub-id pub-id-type="pmid">15897343</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishiyama</surname><given-names>Y</given-names></name><name><surname>Gallagher</surname><given-names>PE</given-names></name><name><surname>Averill</surname><given-names>DB</given-names></name><name><surname>Tallant</surname><given-names>EA</given-names></name><name><surname>Brosnihan</surname><given-names>KB</given-names></name><name><surname>Ferrario</surname><given-names>CM</given-names></name></person-group>
<article-title>Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors</article-title>
<source xml:lang="en">Hypertension</source>
<year>2004</year>
<volume>43</volume>
<issue>(5)</issue>
<fpage>970</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.0000124667.34652.1a</pub-id>
<pub-id pub-id-type="pmid">15007027</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agata</surname><given-names>J</given-names></name><name><surname>Ura</surname><given-names>N</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Shinshi</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Hyakkoku</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme</article-title>
<source xml:lang="en">Hypertens Res</source>
<year>2006</year>
<volume>29</volume>
<issue>(11)</issue>
<fpage>865</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1291/hypres.29.865</pub-id>
<pub-id pub-id-type="pmid">17345786</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>ML</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Ying</surname><given-names>SS</given-names></name><etal/></person-group>
<article-title>Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors</article-title>
<source xml:lang="en">Clin Exp Pharmacol Physiol</source>
<year>2010</year>
<volume>37</volume>
<issue>(1)</issue>
<fpage>e1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1681.2009.05302.x</pub-id>
<pub-id pub-id-type="pmid">19793108</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lambert</surname><given-names>DW</given-names></name><name><surname>Yarski</surname><given-names>M</given-names></name><name><surname>Warner</surname><given-names>FJ</given-names></name><name><surname>Thornhill</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>ET</given-names></name><name><surname>Smith</surname><given-names>AI</given-names></name><etal/></person-group>
<article-title>Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)</article-title>
<source xml:lang="en">J Biol Chem</source>
<year>2005</year>
<volume>280</volume>
<issue>(34)</issue>
<fpage>30113</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M505111200</pub-id>
<pub-id pub-id-type="pmid">15983030</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Epelman</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>WH</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Van Lente</surname><given-names>F</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name></person-group>
<article-title>Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system</article-title>
<source xml:lang="en">J Am Coll Cardiol</source>
<year>2008</year>
<volume>52</volume>
<issue>(9)</issue>
<fpage>750</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2008.02.088</pub-id>
<pub-id pub-id-type="pmid">18718423</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Sriramula</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Moreno-Walton</surname><given-names>L</given-names></name><name><surname>Culicchia</surname><given-names>F</given-names></name><name><surname>Domenig</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension</article-title>
<source xml:lang="en">Circ Res</source>
<year>2017</year>
<volume>121</volume>
<issue>(1)</issue>
<fpage>43</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310509</pub-id>
<pub-id pub-id-type="pmid">28512108</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haga</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Nakai-Murakami</surname><given-names>C</given-names></name><name><surname>Osawa</surname><given-names>Y</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry</article-title>
<source xml:lang="en">Proc Natl Acad Sci U S A</source>
<year>2008</year>
<volume>105</volume>
<issue>(22)</issue>
<fpage>7809</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0711241105</pub-id>
<pub-id pub-id-type="pmid">18490652</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>HP</given-names></name><name><surname>Look</surname><given-names>DC</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Gakhar</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia</article-title>
<source xml:lang="en">Am J Physiol Lung Cell Mol Physiol</source>
<year>2009</year>
<volume>297</volume>
<issue>(1)</issue>
<fpage>L84</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.00071.2009</pub-id>
<pub-id pub-id-type="pmid">19411314</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>R</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group>
<article-title>Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</article-title>
<source xml:lang="en">J Virol</source>
<year>2020</year>
<volume>94</volume>
<issue>(7)</issue>
<comment>pii</comment>
<fpage>e00127</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id>
<pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haga</surname><given-names>S</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds</article-title>
<source xml:lang="en">Antiviral Res</source>
<year>2010</year>
<volume>85</volume>
<issue>(3)</issue>
<fpage>551</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.001</pub-id>
<pub-id pub-id-type="pmid">19995578</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olagnier</surname><given-names>D</given-names></name><name><surname>Scholte</surname><given-names>FE</given-names></name><name><surname>Chiang</surname><given-names>C</given-names></name><name><surname>Albulescu</surname><given-names>IC</given-names></name><name><surname>Nichols</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response</article-title>
<source xml:lang="en">J Virol</source>
<year>2014</year>
<volume>88</volume>
<issue>(8)</issue>
<fpage>4180</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.03114-13</pub-id>
<pub-id pub-id-type="pmid">24478443</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cugola</surname><given-names>FR</given-names></name><name><surname>Fernandes</surname><given-names>IR</given-names></name><name><surname>Russo</surname><given-names>FB</given-names></name><name><surname>Freitas</surname><given-names>BC</given-names></name><name><surname>Dias</surname><given-names>JL</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>KP</given-names></name><etal/></person-group>
<article-title>The Brazilian Zika virus strain causes birth defects in experimental models</article-title>
<source xml:lang="en">Nature</source>
<year>2016</year>
<volume>534</volume>
<issue>(7606)</issue>
<fpage>267</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1038/nature18296</pub-id>
<pub-id pub-id-type="pmid">27279226</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bardina</surname><given-names>SV</given-names></name><name><surname>Bunduc</surname><given-names>P</given-names></name><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>Duehr</surname><given-names>J</given-names></name><name><surname>Frere</surname><given-names>JJ</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity</article-title>
<source xml:lang="en">Science</source>
<year>2017</year>
<volume>356</volume>
<issue>(6334)</issue>
<fpage>175</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1126/science.aal4365</pub-id>
<pub-id pub-id-type="pmid">28360135</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><name><surname>Supasa</surname><given-names>P</given-names></name><name><surname>Wongwiwat</surname><given-names>W</given-names></name><name><surname>Rouvinski</surname><given-names>A</given-names></name><name><surname>Barba-Spaeth</surname><given-names>G</given-names></name><name><surname>Duangchinda</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Dengue virus sero-cross-reactivity drives antibody- dependent enhancement of infection with zika virus</article-title>
<source xml:lang="en">Nat Immunol</source>
<year>2016</year>
<volume>17</volume>
<issue>(9)</issue>
<fpage>1102</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1038/ni.3515</pub-id>
<pub-id pub-id-type="pmid">27339099</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terzian</surname><given-names>ACB</given-names></name><name><surname>Schanoski</surname><given-names>AS</given-names></name><name><surname>Mota</surname><given-names>MTO</given-names></name><name><surname>da Silva</surname><given-names>RA</given-names></name><name><surname>Estofolete</surname><given-names>CF</given-names></name><name><surname>Colombo</surname><given-names>TE</given-names></name><etal/></person-group>
<article-title>Viral Load and Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed Zika Virus-Infected Patients</article-title>
<source xml:lang="en">Clin Infect Dis</source>
<year>2017</year>
<volume>65</volume>
<issue>(8)</issue>
<fpage>1260</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1093/cid/cix558</pub-id>
<pub-id pub-id-type="pmid">29017246</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuzmina</surname><given-names>NA</given-names></name><name><surname>Younan</surname><given-names>P</given-names></name><name><surname>Gilchuk</surname><given-names>P</given-names></name><name><surname>Santos</surname><given-names>RI</given-names></name><name><surname>Flyak</surname><given-names>AI</given-names></name><name><surname>Ilinykh</surname><given-names>PA</given-names></name><etal/></person-group>
<article-title>Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors</article-title>
<source xml:lang="en">Cell Rep</source>
<year>2018</year>
<volume>24</volume>
<issue>(7)</issue>
<fpage>1802</fpage>
<lpage>1815.e5</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.035</pub-id>
<pub-id pub-id-type="pmid">30110637</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willey</surname><given-names>S</given-names></name><name><surname>Aasa-Chapman</surname><given-names>MM</given-names></name><name><surname>O&#x02019;Farrell</surname><given-names>S</given-names></name><name><surname>Pellegrino</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>I</given-names></name><name><surname>Weiss</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection</article-title>
<source xml:lang="en">Retrovirology</source>
<year>2011</year>
<volume>8</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.1186/1742-4690-8-16</pub-id>
<pub-id pub-id-type="pmid">21401915</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuczera</surname><given-names>D</given-names></name><name><surname>Assolini</surname><given-names>JP</given-names></name><name><surname>Tomiotto-Pellissier</surname><given-names>F</given-names></name><name><surname>Pavanelli</surname><given-names>WR</given-names></name><name><surname>Silveira</surname><given-names>GF</given-names></name></person-group>
<article-title>Highlights for Dengue Immunopathogenesis: Antibody-Dependent Enhancement, Cytokine Storm, and Beyond</article-title>
<source xml:lang="en">J Interf Cytokine Res</source>
<year>2018</year>
<volume>38</volume>
<issue>(2)</issue>
<fpage>69</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1089/jir.2017.0037</pub-id>
</element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Functions of TAM RTKs in regulating spermatogenesis and male fertility in mice</article-title>
<source xml:lang="en">Reproduction</source>
<year>2009</year>
<volume>138</volume>
<issue>(4)</issue>
<fpage>655</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1530/REP-09-0101</pub-id>
<pub-id pub-id-type="pmid">19602523</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="book">
<person-group person-group-type="author"><collab>The Protein Cell Atlas Webpage Available from</collab></person-group>
<comment><ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/ENSG00000143226-FCGR2A/tissue">https://www.proteinatlas.org/ENSG00000143226-FCGR2A/tissue</ext-link></comment>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kwok</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title>
<source xml:lang="en">JCI Insight</source>
<year>2019</year>
<volume>4</volume>
<issue>(4)</issue>
<comment>pii</comment>
<fpage>123158</fpage>
<pub-id pub-id-type="doi">10.1172/jci.insight.123158</pub-id>
<pub-id pub-id-type="pmid">30830861</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>CE</given-names></name><etal/></person-group>
<article-title>Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals</article-title>
<source xml:lang="en">J Med Virol</source>
<year>2006</year>
<volume>78</volume>
<issue>(1)</issue>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16299724</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monsalvo</surname><given-names>AC</given-names></name><name><surname>Batalle</surname><given-names>JP</given-names></name><name><surname>Lopez</surname><given-names>MF</given-names></name><name><surname>Krause</surname><given-names>JC</given-names></name><name><surname>Klemenc</surname><given-names>J</given-names></name><name><surname>Hernandez</surname><given-names>JZ</given-names></name><etal/></person-group>
<article-title>Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes</article-title>
<source xml:lang="en">Nat Med</source>
<year>2011</year>
<volume>17</volume>
<issue>(2)</issue>
<fpage>195</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2262</pub-id>
<pub-id pub-id-type="pmid">21131958</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raj</surname><given-names>VS</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Smits</surname><given-names>SL</given-names></name><name><surname>Dekkers</surname><given-names>DH</given-names></name><name><surname>M&#x0fffd;ller</surname><given-names>MA</given-names></name><name><surname>Dijkman</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>
<source xml:lang="en">Nature</source>
<year>2013</year>
<volume>495</volume>
<issue>(7440)</issue>
<fpage>251</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1038/nature12005</pub-id>
<pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kuwahara</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates</article-title>
<source xml:lang="en">ACS Infect Dis</source>
<year>2016</year>
<volume>2</volume>
<issue>(5)</issue>
<fpage>361</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00006</pub-id>
<pub-id pub-id-type="pmid">27627203</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f01" position="float"><label>Figure 1</label><caption><p>Illustrative scheme of ACE-2 expression in the lungs. Left panel: Normally expressed ACE-2 in the lung tissue interacts with SARS-CoV-2. Middle panel: Increased expression of ACE-2 in lung tissues of hypertensive patients under chronic treatment with AT1R blockers. Right panel: ADAM17 cleaves ACE-2, releasing its soluble form, sACE-2, whose levels are increased in the presence of TNF-&#x003b1;. Illustration was developed by the authors using <ext-link ext-link-type="uri" xlink:href="www.biorender.com">www.biorender.com</ext-link>.</p></caption><graphic xlink:href="cln-75-e1912-g001"/></fig><fig id="f02" position="float"><label>Figure 2</label><caption><p>Illustrative scheme of ADE during SARS-CoV-2 infection. Left panel: First infection and lack of preexisting antibodies allow viral particles to interact with ACE-2. Middle panel: Preexisting low-affinity antibodies or antibodies at sub-optimal concentrations bind to viral particles and facilitate the viral internalization mediated by FcRs expressed on either the epithelial or immune cells. Right panel: Neutralizing IgGs elicited in response to vaccination, or neutralizing IgM that do not mediate enhancement bind to viral particles. Illustration created by the authors using <ext-link ext-link-type="uri" xlink:href="www.biorender.com">www.biorender.com</ext-link>.</p></caption><graphic xlink:href="cln-75-e1912-g002"/></fig></floats-group></article>